Clinical Decision Support software is any digital system that helps healthcare workers. It gathers and studies medical data. Then, it gives advice or alerts about diagnosis, treatment, or disease prevention. These tools can be simple or complex. For example, some CDS tools do basic math like calculating body mass index (BMI) or blood pressure averages. Others use advanced artificial intelligence to predict patient outcomes or suggest treatments tailored to the patient.<\/p>\n
CDS tools often connect to Electronic Health Records (EHRs) or hospital systems. They give real-time help during patient care. Examples include alerts for drug interactions, calculators for dosing, warnings about sepsis, and AI models that predict risks like stroke or addiction.<\/p>\n
The FDA watches over clinical decision support tools as part of Software as a Medical Device (SaMD). SaMD means software intended for medical use that works on its own, not as part of a machine. Since 2016, the 21st Century Cures Act clarified how the FDA categorizes and regulates software. It separates software that needs FDA regulation from that which does not.<\/p>\n
Whether a CDS tool is regulated depends mainly on its “intended use.” This is how the software is described, marketed, and used. If the software aims to “diagnose,” “treat,” “reduce,” or “prevent” disease, then it usually falls under FDA rules.<\/p>\n
Not all CDS programs are medical devices that the FDA must regulate. Section 3060 of the 21st Century Cures Act states that some CDS tools are exempt if they meet four rules:<\/p>\n
Tools that pass these rules are considered helpers, not decision-makers, so they do not need FDA approval.<\/p>\n
In September 2022, the FDA released final guidance on Clinical Decision Support Software. This update removed some of the earlier rules on when the FDA might choose not to enforce regulations. The FDA now plans to supervise more CDS tools.<\/p>\n
One concern is automation bias. This happens when doctors rely too much on software without their own judgment. This worry grows if the software gives one clear treatment choice without explaining why.<\/p>\n
If a CDS tool follows known clinical rules and FDA-approved instructions, the FDA is less likely to intervene. But software that strays from accepted practices or gives strict treatment orders without room for review will probably need FDA approval and control.<\/p>\n
The FDA and international groups like the International Medical Device Regulators Forum classify SaMD based on risk. The risk level depends on two things:<\/p>\n
Most CDS tools fall into low-risk groups (Class I or II). They offer information but let healthcare workers use their judgment. High-risk tools that directly control important treatment or diagnosis parts must follow strict regulations (Class III).<\/p>\n
Medical practice managers and IT leaders face many issues with these rules:<\/p>\n
<\/p>\n